Your Liver and Your Insulin Are Fighting Each Other — Here's Who's Winning

You’re eating better. You’re moving more. Maybe you’ve even cut back on alcohol. And yet — the energy isn’t coming back. The weight isn’t shifting. The labs aren’t improving the way they should.

Here’s what most people — and most doctors — are missing: fatty liver and insulin resistance don’t operate independently. They form a loop. Each one makes the other worse, and if you’re only treating one side of that equation, you’re running in circles.

One in four people have a fatty liver. One in three are pre-diabetic or insulin resistant. The research is clear: these two conditions almost always show up together, and they’re not a coincidence — they’re a consequence.

Understanding this loop is the first step to breaking it.

The number one driver of both fatty liver and insulin resistance is diet — specifically the chronic overconsumption of refined carbohydrates. Bread, rice, pasta, tortillas, processed snack foods, sweetened beverages. These foods break down into glucose, which insulin shuttles into the liver for storage. When there’s too much, too often, the liver gets overwhelmed. It starts storing fat. That’s how a fatty liver develops.

But here’s what makes this a loop rather than a one-time problem: a fatty liver doesn’t process insulin efficiently. Research shows the liver is responsible for degrading approximately 50% of the body’s secreted insulin through an enzyme called insulin-degrading enzyme (IDE). When the liver is congested with fat, that process breaks down. Insulin levels rise. Higher insulin drives more fat storage into the liver. The liver gets fattier. Insulin rises further.

What makes this worse over time:

• Refined carbohydrates elevate blood sugar repeatedly throughout the day
• The liver runs out of storage capacity and begins diverting fat elsewhere
• Insulin signaling becomes impaired across multiple organ systems
• Advanced glycation end products (AGEs) begin accumulating — in the liver, in the brain, in blood vessel walls

This isn’t about one bad meal. It’s about years of dietary patterns that quietly push the liver and the insulin system past their limits. Research confirms that insulin resistance and obesity are the two primary precursors to non-alcoholic fatty liver disease (NAFLD) — meaning by the time a fatty liver is diagnosed, the metabolic damage has often been building for a decade or more.

Most people don’t know they have a fatty liver or chronically elevated insulin until the consequences show up — and by then, the loop has been running for years.

Here’s what this looks like in the body over time:

Digestive dysfunction comes first. The liver and the gut are in constant communication. When the liver is congested, digestion suffers. Bloating, constipation, SIBO, irritable bowel syndrome, and gallbladder problems are among the most common early consequences of unchecked fatty liver and insulin resistance.

Chronic fatigue follows. A sluggish liver is an energy-depleting liver. The mitochondrial and metabolic burden of processing excess glucose and fat leaves the body running at a deficit. If you’re tired all the time despite reasonable sleep and nutrition, your liver and blood sugar deserve a closer look.

Then come the risks most people aren’t warned about.

Research published in peer-reviewed literature has established a direct link between non-alcoholic fatty liver disease and colorectal cancer risk. The mechanism runs through two hormones most doctors are not testing: adiponectin and leptin.

Adiponectin is an anti-inflammatory hormone produced by fat cells. It inhibits tumor necrosis factor alpha (TNF-α), reduces cancer cell proliferation, and plays a direct role in protecting against colorectal cancer. In people with NAFLD, adiponectin levels are consistently low.

Leptin, on the other hand, rises as adiponectin falls. Leptin is elevated in obesity, type 2 diabetes, and colorectal cancer — and research has confirmed that leptin can induce carcinogenesis, meaning it actively supports the conditions under which cancer cells grow.

And the loop doesn’t stop at cancer. Patients with NAFLD show significantly higher rates of dementia and cognitive decline. Insulin resistance, chronic inflammation, gut microbiota disruption, and hyperammonemia — all downstream consequences of fatty liver — are each independently linked to neurological impairment. If you outlive the liver disease and the diabetes, the dementia risk is waiting on the other side.

The same thing that started this loop can end it. Diet is where the reversal begins — and the research is specific about what works.

Fasting + the Mediterranean Diet

Alternate-day fasting combined with a Mediterranean dietary pattern has been shown to improve insulin sensitivity, reduce liver fat, and lower liver enzyme markers (ALT) within months. Even without weight loss, the Mediterranean diet alone has been shown to reduce liver steatosis and improve insulin sensitivity in people with NAFLD.

The Mediterranean diet is high in antioxidants, fiber, monounsaturated fatty acids, and omega-3s. It is low in saturated fats, refined carbohydrates, and processed foods — the exact opposite of what drives fatty liver and insulin resistance in the first place.

Resistance Training

Exercise matters — and the research points specifically to resistance training. Studies have shown that weeks of resistance exercise produce a 13% relative reduction in liver lipid, with improvements in glucose control and insulin resistance across the board. Walking is beneficial, but adding weight training accelerates the metabolic shift in ways that cardio alone cannot match.

The Labs to Track

If you want to know where you stand, these are the four markers worth requesting:

• Insulin — should be low
• Adiponectin — should be high
• Leptin — should be low
• GGT — the direct fatty liver enzyme marker, should be low

Most standard panels don’t include adiponectin or leptin. Ask specifically. These numbers tell a more complete metabolic story than fasting glucose or standard liver panels alone.

Supplementation

Berberine is one of the most well-researched compounds for this specific set of conditions. Clinical research has shown it lowers insulin, reduces TNF-α and IL-6, activates AMPK and PPAR pathways, and increases adiponectin — making it one of the few supplements that directly addresses multiple points in this loop simultaneously. The dihydroberberine form used in Berberine Plus from MSW Nutrition offers five times greater bioavailability than standard berberine.

Paired with Liver Boost for direct liver support and Gut Powder for the digestive consequences, the Good Poops Protocol covers all three systems this episode addresses.

Fatty liver and insulin resistance are not two separate problems. They are one loop — and that loop, left unchecked, extends its reach into the gut, the colon, and the brain. The research on this is not new. The connection between NAFLD, colorectal cancer, dementia, and type 2 diabetes has been building in the literature for decades.

What’s new is the conversation — and the practical tools to do something about it.

Start with diet. Add fasting. Lift weights. Get the right labs. Support your liver, your blood sugar, and your gut with supplements that are actually built for this.

You can break the loop. The biology is on your side when you give it what it needs.

1. NAFLD pathophysiology — insulin resistance and obesity as precursor stages to steatosis https://pmc.ncbi.nlm.nih.gov/articles/PMC10638269/
2. Liver glucose homeostasis and insulin degradation via IDE https://pmc.ncbi.nlm.nih.gov/articles/PMC11850106/
3. Peripheral insulin resistance, IDE, and advanced glycation end product accumulation https://pmc.ncbi.nlm.nih.gov/articles/PMC8472298/
4. Adiponectin, leptin, NAFLD, and colorectal cancer risk — HbA1c and 33% increased CRC risk per 1% increase https://pmc.ncbi.nlm.nih.gov/articles/PMC3523590/
5. NAFLD, dementia, and cognitive impairment — insulin resistance, hyperammonemia, and inflammation as neurological drivers https://pubmed.ncbi.nlm.nih.gov/35831178/
6. Alternate-day fasting and fatty liver — improved insulin sensitivity, reduced liver fat, lower ALT https://today.uic.edu/alternate-day-fasting-a-good-option-for-patients-with-fatty-liver-disease/
7. Mediterranean diet, metabolic syndrome, and type 2 diabetes https://pmc.ncbi.nlm.nih.gov/articles/PMC5960814/
8. Mediterranean diet reducing liver steatosis and improving insulin sensitivity without weight loss https://www.sciencedirect.com/science/article/abs/pii/S0168827813001347
9. Resistance training and 13% reduction in liver lipid with improved insulin resistance https://gut.bmj.com/content/60/9/1278
10. Berberine in NAFLD, obesity, and diabetes — AMPK, PPAR, adiponectin increase, TNF-α and IL-6 reduction https://pmc.ncbi.nlm.nih.gov/articles/PMC12833932/